Board Members

Board Members

Dr. Chris Hentschel is the Founding former CEO and Board member of Medicines for Malaria Venture (Geneva) and of the MRC Collaborative Center (London). Dr. Hentschel is a life science leader and innovator with extensive networks and knowledge in biomedical research, global public health and public-private partnerships. He served on the Roll Back Malaria Partnership Executive Board, as a member of the UK Medical Research Council Global Health Group, and as an IKEA Foundation advisory board member. He is currently also serving on the boards of the Infectious Disease Research Institute (IDRI, Seattle), the Global Medical Forum Foundation (GMF, Zurich, MSM Protein technologies, Boston, and as a partner of Life Science Ventures (LSV, Cayman Islands) Management Advisory Board.

Charles Osei-Akoto has about 25 years of experience in the actuarial, insurance and consulting industries, spending the first 14 years with some of the largest companies in the US. A Ghana native, Mr. Osei-Akoto established UNIQUE Insurance Company (Ghana) and ran the company as the premiere Managing Director for four years, after which he established Stallion Consultants Ltd. where he has been since 2004. As the Executive Chairman of Stallion Consultants Limited, an actuarial and management consulting firm domiciled in Accra-Ghana, he provides leadership for the company. He is a qualified Actuary with the Society of Actuaries. (U.S.) and also a Member of the American Academy of Actuaries (MAAA). Mr. Osei-Akoto holds a Bachelor of Science Degree in Actuarial Science, and a Master of Business Administration (MBA-Finance), both degrees from the University of Michigan, Ann Arbor, U.S.A.

Dr. Robert Ridley’s career spans both the public and private sectors. He is currently Pro Vice Chancellor at the University of Malawi, after leaving a position as Director of Tropical Disease Research within the World Health Organization to which he was appointed in 2004. Prior to this, he held the position of Coordinator, Product Research and Development, WHO/TDR, which covers projects relating to drugs, vaccines and diagnostics. He has an academic background that covers the fields of organic chemistry, biochemistry and molecular biology, with positions at the University of Malawi (1980-83), McMaster University, Canada (1983-86) and Edinburgh University in the U.K.(1986-92). In 1992 he moved to industry, working for F. Hoffmann-La-Roche Ltd. in Basel (Switzerland), where he was a Vice Director in the Infectious Diseases Drug Discovery department. Since 1997 he has been heavily engaged in broader issues relating to public sector interactions with the pharmaceutical industry, including the establishment of the Medicines for Malaria Venture, for which he acted as Chief Executive Officer from early 1999 to early 2000. During his tenure with TDR he has also been heavily involved in issues related to the use of drugs and the economics and financing of their provision in resource poor settings. He has published widely on malaria research related to drug and vaccine discovery and development.